GLUE
Monte Rosa Therapeutics, Inc.
There isn't enough reported data to score GLUE yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
GLUE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
GLUE's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GLUE PE Valuation
GLUE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GLUE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GLUE's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GLUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.40 | -489% |
| Q2 2026 | -$1.76 | -540% |
| Q1 2026 | -$1.48 | -1333% |
| Q4 2025 | -$0.46 | +$0.52 |
| Q3 2025 | $0.36 | +$2.18 |
| Q2 2025 | $0.40 | +$2.63 |
| Q1 2025 | $0.12 | +$2.63 |
| Q4 2024 | -$0.98 | +$1.65 |
GLUE has swung to a loss: it lost $1.40 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over GLUE on earnings quality, reporting a profit while its opponent remains loss making.
GLUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.4M | +326% |
| Q2 2026 | $9M | -61% |
| Q1 2026 | $4.2M | -95% |
| Q4 2025 | $2.8M | -95% |
| Q3 2025 | $12.8M | +39% |
| Q2 2025 | $23.2M | +394% |
| Q1 2025 | $84.9M | +7882% |
GLUE's revenue is recovering but still below its 2025 peak: $54M last quarter, up 326% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.6% | +255 points |
| Q2 2026 | -548% | -481 points |
| Q1 2026 | -1188% | -1240 points |
| Q4 2025 | -1788% | -1809 points |
| Q3 2025 | -258% | +30 points |
| Q2 2025 | -67% | +628 points |
| Q1 2025 | 52% | +3336 points |
| Q4 2024 | 21% | N/A |
GLUE's operating margin was −3.6% last quarter, up 255 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GLUE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over GLUE on profitability, with a higher operating margin.
GLUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.5M | -143% |
| Q2 2026 | -$48.8M | -$12.4M |
| Q1 2026 | -$39.2M | +$7.8M |
| Q4 2025 | -$43.8M | -134% |
| Q3 2025 | $99.8M | +$121.2M |
| Q2 2025 | -$36.4M | -$6.6M |
| Q1 2025 | -$47.1M | -$7.5M |
| Q4 2024 | $128.7M | +361% |
GLUE has burned cash in almost every quarter: −$174M over the past year, against $145M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GLUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GLUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.1M shares |
| 1 year | +32% | +26.2M shares |
| 3 years | +118% | +58.8M shares |
| 5 years | +155% | +66.1M shares |
| Available history | +400% | +86.9M shares |
GLUE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $178,000 |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GLUE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -11.2x | Net Cash |
| Q2 2025 | -2.8x | Net Cash |
| Q1 2025 | -10.4x | Net Cash |
GLUE has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GLUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 6.7 | Oversold |
GLUE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GLUE PE vs Healthcare Sector
| Metric | GLUE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GLUE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GLUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 11% below |
| 20 week MA | $14.7 | 37% below |
| 50 week MA | $17.0 | 45% below |
| 100 week MA | $11.8 | 21% below |
| 200 week MA | $8.82 | 5.6% above |
GLUE has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over GLUE on trend strength, trading above more of its moving averages.
GLUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.9 | $20.9 | +11% |
| 2022 | $20.9 | $7.94 | -62% |
| 2023 | $7.94 | $5.65 | -29% |
| 2024 | $5.65 | $7.06 | +25% |
| 2025 | $7.06 | $17.3 | +145% |
| 2026 YTD | $17.3 | $9.31 | -46% |
GLUE's yearly returns have swung widely, from +145% in 2025 to −62% in 2022. It's down 46% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GLUE on returns for 2026, with the stronger performance.